Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib, Cyclophosphamide, and Etoposide for Pediatric Relapsed/Refractory Solid Tumors and Leukemias
NCT02512926Phase 1Completed
- Sponsor
- Stanford University
- Start
- Feb 2016
- Primary completion
- Aug 2021
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 2
01
Overview
Phase 1, open-label trial of carfilzomib in solid tumor and leukemia, sponsored by Stanford University. Started Feb 2016; status: completed.
02
Drugs
carfilzomib
03
Conditions
solid tumorleukemia
Beyond the preview
Go deeper on NCT02512926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02512926.